Despite prompt epicardial recanalization in patients presenting with ST-segment elevation
myocardial infarction (STEMI), coronary microvascular obstruction and dysfunction (CMVO) …

Abstract The glycoprotein (GP) IIb/IIIa receptor is found integrin present in platelet
aggregations. GP IIb/IIIa antagonists interfere with platelet cross-linking and platelet-derived …

Background Intracoronary (IC) administration of glycoprotein IIb/IIIa inhibitors (GPIs) has
been studied as an adjunctive therapy to improve outcomes in patients with ST-segment …

Although the widespread adoption of timely invasive reperfusion strategies over the last two
decades has significantly improved the prognosis of patients with ST-segment elevation …

Background: To determine whether intracoronary pro-urokinase or tirofiban improves
myocardial reperfusion during primary percutaneous coronary intervention (PCI) for acute …

The goal of reperfusion therapies in ST-segment elevation myocardial infarction has evolved
to include effective reperfusion of the microcirculation subtended by the culprit epicardial …

Platelet glycoprotein IIb/IIIa inhibitors (GPI) are antithrombotic agents preventing the binding
of fibrinogen to GP IIb/IIIa receptors. Thus, GPI interfere with interplatelet bridging mediated …

Coronary microvascular dysfunction (CMD) has emerged as an important therapeutic target
in the contemporary management of ischemic heart disease. However, due to a lack of a …

We evaluated the acute effect of intracoronary administration of tirofiban on no-reflow
phenomenon in patients with ST-segment elevated myocardial infarction undergoing …

Background Up to 50% of acute myocardial infarction (MI) patients present with
microvascular dysfunction, after a successful percutaneous coronary intervention (PCI) …